Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,901–3,000 of 3,636
Update Lipidologie: Evidenzbasierte Behandlung von Fettstoffwechselstörungen
Parhofer, K. G. (2020) · Der Internist · doi:10.1007/s00108-020-00799-9
Regression of coronary atherosclerosis in light of recent studies
Kovárník, T., & Kopřiva, K. (2019) · Intervenční a akutní kardiologie · doi:10.36290/kar.2019.024
“U vysoce rizikové skupiny nemocných – pacientů po akutním koronárním syndromu – vedla ve studii ODYSSEY OUTCOMES (32) terapie alirocumabem v kombinaci se statiny k signifi-”
BackgroundSafety of Evolocumab in People Living With HIV Infection
Nambi, V., Hussain, A., & Stein, J. H. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.062
Lipidtherapie zur kardiovaskulären Prävention bei Diabetes mellitus
Merkel, M. (2020) · CardioVasc · doi:10.1007/s15027-020-2112-1
“Dies konnte auch in den aktuellen prospektiven Endpunkstudien mit PCSK9-Inhibitoren (FOURIER und ODYSSEY outcomes) nachgewiesen werden [7, 8].”
BackgroundType 2 Myocardial Infarction and Injury
Dahhan, A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.088
Kong, N., Bavishi, A. A., Amaral, A. P., Tibrewala, A., Jivan, A., Silberman, P., & Stone, N. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.039
Challenges in constructing genetic instruments for pharmacologic therapiesPreprint
Ference, B. A., Smith, G. D., Holmes, M. V., Catapano, A. L., Ray, K. K., & Nicholls, S. J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.13115 · Cited by 1
IuA, K., & Moscow, R. F. (2020) · Doctor Ru · doi:10.31550/1727-2378-2020-19-5-42-49
“Особенно следует подчеркнуть, что выгоды, связанные с уменьшением уровня ХсЛПНП, являются неспецифическими для статинотерапии и отмечались при его дополнительном снижении вследствие присоединения к статинам эзетимиба в исследовании IMPROVE-IT [10] и эволокумаба или алирокумаба в исследованиях ODYSSEY [13] и FOURIER [1…”
2019 Leitlinie Dyslipidämie kompakt: Was ist neu?
Weingärtner, O., Landmesser, U., Laufs, U., & März, W. (2020) · Der Klinikarzt · doi:10.1055/a-1237-3557
Bempedoic acid: A new player in lipid-lowering therapies
Cuevas, A. M., & Rodrigo Alonso, K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.014
Universal cholesterol screening of youth—Are pediatric lipidologists smarter than a fifth grader?
Kohn, B., & Wilson, D. P. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.09.007
ESC-Leitlinie Dyslipidämien: die 10 Kernbotschaften
Toussaint, K., & Brückner, C. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-0523-7
Szulc-Bagrowska, J., Szepietowski, B., & Lelonek, M. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0033
Packard, C. J. (2020) · Circulation · doi:10.1161/circulationaha.120.050070
Hot Topics in Primary Care 2020 Introduction
Brunton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0058
Familial Hypercholesterolaemia: An Updated Overall Management
Kasim, N. A. M., Chua, Y. A., & Nawawi, H. M. (2020) · Journal of Clinical and Health Sciences · doi:10.24191/jchs.v5i2.11121 · Cited by 2
Escobar, C., & Barrios, V. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30026-1
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30024-8 · Cited by 1
Masson, W. M., Barbagelata, L., Lee, M., Siniawski, D. A., Estrada, J. L. N., Arias, A., Cagide, A. M., & Pizarro, R. (2020) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v88.i5.19021
Pedro‐Botet, J., & Climent, E. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.12.007
Orringer, C. E., & Stone, N. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_6
The Low-Density Lipoprotein Cholesterol Hypothesis: An Update
Rengarajan, R., Tecson, K. M., & McCullough, P. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_7
How ApoB Measurements Could Improve Prevention of Cardiovascular Disease
Sniderman, A. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_29
Is LDL apheresis a thing of the past?
Vally, M., Khan, R., & Orchard, A. (2020) · South African General Practitioner · doi:10.36303/sagp.2020.1.4.0034
Genetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 2
Cardiovascular Disease in Women: Focus on Lipid Management
Morris, P. B., Aspry, K. E., Watson, K. E., Wild, R. A., & Bittner, V. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_24
Self-citationPCSK9-Inhibitoren - Erfahrungen im klinischen Alltag
Kassner, U., & Hollstein, T. (2020) · CardioVasc · doi:10.1007/s15027-020-3423-y
“In großen multizentrischen Studien konnte gezeigt werden, dass schon eine LDL-C-Senkung um 1 mmol/l (39 mg/dl) das jährliche Risiko für kardiovaskuläre Ereignisse um ca. ein Fünftel senkt [3].”
BackgroundInfluentialKao, Y.-C., Chen, T., Liu, C., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-74077/v1
“For either primary or secondary prevention of CV diseases, the concept of “the lower, the better” is veri ed from the results of numerous trials 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) and landmark studies of non-statin LDL-C lowering agents, such as ezetimibe [9, 10] or proprotei…”
BackgroundEmerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Doğrul, H., Doğaner, Y. Ç., & Aydoğan, Ü. (2020) · Eurasian Journal of Family Medicine · doi:10.33880/ejfm.2020090401
Kam, W., & Husseini, N. E. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_24
Utility and Appropriate Use of PCSK9 Inhibitors in the Current Era
Singh, A., Huffman, T. R., & Smith, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95238
The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction
Dembowski, E., Grundy, S. M., & Stone, N. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_10
Klooster, C. C. V. ’. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/105 · Cited by 1
Brunzell, J. D., & Failor, R. A. (2018) · DeckerMed Medicine · doi:10.2310/fm.1569
Smulders, Y. M. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa018
Sinning, D., & Landmesser, U. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1199-8496
“Mit Blick auf den kombinierten Endpunkt zeigte sich kürzlich in einer Subgruppenanalyse zu älteren Teilnehmern (> 75 Jahre) der IMPROVE-IT-Studie ein besonders großer Vorteil für die Kombinationstherapie von Ezetimib und Statin im Vergleich zur Statin-Monotherapie [10].”
BackgroundInfluentialde Vries, T. I. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/352
Primary prevention of Cardiovascular Diseases among the Middle aged and the Elderly
Omer, N. M. A. A., Yousuf, W., & Mansouri, N. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93997
Foot care among recently diagnosed diabetic patients in Muhayel, Aseer Region, Saudi Arabia
Hassan, A., Al-Khaldi, Y. M., Mawkili, B. M. K., Al-Mudawi, B. A. M., & Alasmari, A. A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93978
Aldhabaan, W. A., Asiri, B. B. S. A., & Alahmari, A. S. M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93987 · Cited by 1
Minor Head Injury: Quality Improvement Project
Shaheen, S., Hameed, M., & Qabeel, Y. E. H. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93980
Management of depression in primary care - A cross-sectional study in the North-East of England, UK
Hegde, R., Gunputh, P., & Sinha, B. N. P. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93998
Guideline recommendations, clinical trial data, and new and emerging therapies
Lindsley, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88607 · Cited by 1
Finalement, jusqu’où faut-il baisser le LDL-cholestérol et comment ?
Béliard, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.011 · Cited by 1
Corral, P., López, A. A. P., Giunta, G. A., Buitrago, A. F., & Saraiva, J. F. K. (2021) · doi:10.22541/au.161548923.32347892/v1
Review of LDL-C Lowering with Focus on New and Emerging Agents
Brinton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0070
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
Bakris (2020) · The Journal of Family Practice · doi:10.12788/jfp.0072
Chaulin, A. M., Svechkov, N. A., & Duplyakov, D. V. (2021) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2021-6-1-54-60 · Cited by 2
Vesa, C. M., Popa, A. R., Popoviciu, M. S., Popa, L., Popescu, M. I., Sabau, M., Daina, L., & Carp, G. (2021) · Internal Medicine · doi:10.2478/inmed-2021-0149
A New Era in Asthma Management: Assessment of Asthma Control
Murphy, M. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0061
Monroe, L., Evans, T. G., Thacker, T., et al. (2021) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001239
The concept of “preventive” interventional cardiology: from imaging to stenting and beyond
Dimitriadis, K. S., Dri, E., & Tsioufis, C. P. (2021) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2021.03.007
Desarrollo clínico de ácido bempedoico: estudios fase 2 y fase 3
Lekuona, I., & Pintó, X. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.005 · Cited by 1
Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?
Soška, V., & Kyselák, O. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.034
“Pro oba PCSK9-i máme z klinických studií také důkazy o tom, že jejich přidání ke statinům u pacientů v sekundární prevenci dále snižuje kardiovaskulární mortalitu a morbiditu (11, 12).”
Prevención secundaria en el paciente coronario
Sorbets, E., Lallmahomed, E., Kretz, S., Cinaud, A., Vallée, A., Lelong, H., Blachier, V., & Blacher, J. (2021) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(21)44686-6
Socioeconomic status and myocardial infarction : influence on secondary prevention and prognosis
Ohm, J. (2021) · Figshare
Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy
Povero, M., Pradelli, L., Serra, A., Fanelli, F., & Gazzi, L. (2021) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v22i1.1499
Statin Intolerance: Alternative Therapy for Lipid Management
Cross, L. V., & Mattingly, J. (2021) · ADCES in Practice · doi:10.1177/2633559x20972355
“93).(6) PCSK9 inhibitors are potent agents that can lower LDL-C significantly, especially when added to statin therapy.”
BackgroundMethodMyocardial Infarction and Evolocumab—Reply
Wiviott, S. D., Giugliano, R. P., & Sabatine, M. S. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2000
de Araújo, A. L. V. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-30062021-101731 · Cited by 1
Barrios, V., Escobar, C., Arrarte, V., Bravo, M., del Campo, A., Hidalgo, R., Recasens, L., & Cequier, A. R. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.05.003 · Cited by 2
Impact of Nutrition on Biomarkers of Cardiovascular Health
Ormiston, C. K., Ocher, R., & Taub, P. R. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_2
Dietary Approaches to Lowering LDL-C
Chevli, P. A., & Shapiro, M. D. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_13
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225 · Cited by 3
Improving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Understanding of Clinical Practice Guidelines for Dyslipidemia
Rhee, E. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_13 · Cited by 1
Zhou, G., Wang, P., Lu, S., Wang, C., Xie, Z., Cao, W., Shi, J., Zhu, W., Wang, R., Zhou, G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3911102
Lipid-lowering therapy in special situations
Ватутин, Н. Т., Тарадин, Г. Г., Rakitskaya, I. V., Kharchenko, A. V., Stekhina, K. V., Linnik, I. G., Борт, Д. В., Гасендич, Е. С., & Mogilevskaya, K. E. (2021) · Health Food & Biotechnology · doi:10.36107/hfb.2020.i4.s88
Windler, E. E. T., Zyriax, B., & Augustin, M. (2021) · Gynäkologische Endokrinologie · doi:10.1007/s10304-021-00418-2
“Sie hemmen das den Abbau von LDL-Rezeptoren regulierende PCSK9, sodass eine größere Zahl LDL-Rezeptoren demBlut LDL entzieht und Senkungen des LDL-Cholesterins von 60–80% erreichbar sind [33, 34].”
BackgroundNeue Therapieansätze in der LDL-Cholesterin-Absenkung?
Schettler, V. J. J. (2021) · Dialyse aktuell · doi:10.1055/a-1401-3142
“1056/ NEJMoa1615664 [13] Schwartz GG, Steg PG, Szarek M et al.”
BackgroundInfluentialPérez, A., de Victoria, E. O. M., Arrieta, F., Caixàs, A., Mazo, E. S., Fernández-Catalina, P., Martínez‐Hervás, S., Medina, J. A., Suárez-Gutiérrez, L., Planelles, J. R. U., et al. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.07.009
Wang, J. (2019) · University of Minnesota Digital Conservancy (University of Minnesota)
Pro a předem prohraný souboj proti PCSK9 inhibitorům
Zafarová, Z. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.100
Neues beim Schlaganfall: Prävention
Diener, H., Endres, M., Fiehler, J., Gerloff, C. P., Häusler, K. G., Kuramatsu, J. B., Pfeilschifter, W., Poli, S., Purrucker, J. C., Schnabel, R. B., et al. (2021) · Geriatrie up2date · doi:10.1055/a-1388-0720
“In der ODYSSEY-Studie (Alirocumab) war der präventive Effekt auf den Endpunkt Schlaganfall auch signifikant (HR: 0,73; 95%-KI: 0,57–0,93) [5].”
BackgroundNew Agents for Treatment of Dyslipidemia
Simha, V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch17
Therapie und Risikoabschätzung bei Fettstoffwechselstörungen
Parhofer, K. G. (2021) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-021-0282-0
Peligro: se ha detectado un cortocircuito en la prescripción de los inhibidores de PCSK9
Pedro‐Botet, J., & Climent, E. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.11.001
Роль средств массовой информации в культурном взаимообмене в период хрущевской «Оттепели»
Вагизовна, Д. Р. (2010) · Ученые записки Казанского университета. Серия Гуманитарные науки
[ON THE BEHAVIOR OF BLOOD SUGAR CURVES IN MULTIPLE SCLEROSIS PATIENTS].
Warecka, K. (1963) · PubMed
Simulación de negocio jurídico y falsedad documental
Zapater, E. B. (1998) · La Ley: Revista jurídica española de doctrina, jurisprudencia y bibliografía
Kardiovaskuläre Hochrisikopatienten: Hilfe bei der LDL-C-Zielwerterreichung
Makhmudova, U., Schulze, P. C., Vogt, A., & Weingärtner, O. (2021) · CardioVasc · doi:10.1007/s15027-021-3603-4 · Cited by 1
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_9-1
The ‘real world’ is relative—biased
Kränkel, N. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab227
Warning: a short circuit has been detected in the prescription of PCSK9 inhibitors
Pedro‐Botet, J., & Climent, E. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.11.007
Traitement médical de l’artériopathie athéromateuse des membres inférieurs
Sitruk, J., Goudot, G., Mohamedi, N., & Messas, E. (2021) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2021.11.007
Faculty Opinions recommendation of Effect of alirocumab on mortality after acute coronary syndromes.
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735819386.793563697
Klose, G., & Schirmer, B. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_31
Gallagher, A., Agresta, B., Smyth, B. J., Jardine, M., Ferro, C. J., & Morton, R. L. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab288
Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung
Neumann, F. (2019) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2019.10.04.01
Herzinfarkt: Was kommt in den Jahren danach?
Zeymer, U. (2019) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2019.10.04.05
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch24
2022 Summary of recommendations for long-term secondary prevention after myocardial infarction
Ošťádal, P., Táborský, M., Linhart, A., Vrablík, M., Češka, R., Cífková, R., Králíková, E., Adámková, V., Prázný, M., & Jojko, Z. (2022) · Cor et Vasa · doi:10.33678/cor.2021.140
Pharmacology for cardiovascular nurses
Keenan, J., Khatib, R., McKee, G., Ruppar, T. M., & Wilson, F. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849315.003.0012
Percussion in Cardiovascular Examination of a Tombstone
Malvi, A., & Acharya, S. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i60b34833
“measurements, and Bland-Altman plots were created to look at any estimations [23-29].”
MethodA Study Protocol on Assessment of ECG and Echocardiography Changes in Stroke Patients
Nagdev, G., & Gawande, V. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i60b34960 · Cited by 1
“Articles related to different aspects of this study and cardiovascular investigations were reported [22-25].”
BackgroundShe, J., Lou, B., Liu, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1329394/v1
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

